Mycophenolic Acid in Plasma/Serum - HPLC

Clinical relevance

Mycophenolic acid (MPA) is used as an immunosuppressant agent to prevent organ transplant rejection. It is also used to treat autoimmune disorders with chronic inflammation of the skin (psoriasis), eyes, and the digestive tract (Crohn's disease).

Currently available drugs contain mycophenolate mofetil or mycophenolate sodium, which are both completely metabolised into the active metabolite MPA. MPA is partially further metabolised into the inactive mycophenolate glucuronide (MPAG), which then can undergo deglucuronidation in the enterohepatic circulation system and is available again in the body as an active metabolite. Therapeutic monitoring of MPA is required to reach blood concentrations within the therapeutic window to achieve a favourable ratio between therapeutic effects and side effects for the patient.

The Chromsystems assay allows the quantitative detection of mycophenolic acid in human plasma or serum samples by HPLC (high performance liquid chromatography).
It is intended as a monitoring test for patients treated with mycophenolate mofetil or mycophenolate sodium as an aid to ensure drug levels are maintained within the therapeutic range.

Product advantages

• Fast and easy sample preparation
• Detection of physiologically active MPA

Assay characteristics

Sample preparation is performed by means of selective solid phase extraction, in which physiologically inactive MPAG is separated. The analyte is quantified by the inclusion of an internal standard to compensate losses during sample preparation.

Our TDM Parameter Set Mycophenolic Acid from the MassTox® TDM Series A is available as an alternative for the measurement of MPA and MPAG using LC-MS/MS.

Detailed performance evaluation data for this assay can be found in the appendices of the instruction manual.